{"id":"fondaparinux-ufh-not-indicated","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Major bleeding"},{"rate":"1-2%","effect":"Thrombocytopenia"},{"rate":"1-2%","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1201202","moleculeType":"Oligosaccharide","molecularWeight":"1508.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to antithrombin III, enhancing its ability to inactivate factor Xa. This leads to a decrease in thrombin formation and subsequent clotting. Fondaparinux has a longer half-life compared to heparin, allowing for once-daily dosing.","oneSentence":"Fondaparinux is a synthetic anticoagulant that selectively inhibits factor Xa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:58.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Deep vein thrombosis"},{"name":"Pulmonary embolism"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT00790907","phase":"PHASE4","title":"Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute Coronary Syndrome","enrollment":3235},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":237,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"fondaparinux - UFH not indicated","genericName":"fondaparinux - UFH not indicated","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fondaparinux is a synthetic anticoagulant that selectively inhibits factor Xa. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}